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PPRE-CLINICAL RESEARCH
Cardiac Deletion of the Coxsackievirus-
Adenovirus Receptor Abolishes Coxsackievirus B3
Infection and Prevents Myocarditis In Vivo
Yu Shi, MD, PHD,* Chen Chen, MSC,* Ulrike Lisewski, MSC,* Uta Wrackmeyer, MSC,*
Michael Radke, PHD,* Dirk Westermann, MD,† Martina Sauter, DVM,‡ Carsten Tschöpe, MD,†
Wolfgang Poller, MD,† Karin Klingel, MD,‡ Michael Gotthardt, MD*§
Berlin and Tübingen, Germany; and Pullman, Washington
Objectives We investigated the role of the Coxsackievirus-adenovirus receptor (CAR) in viral myocarditis.
Background CAR is involved in virus uptake into various cell types. It has therefore been suggested as a therapeutic target to
prevent or treat Coxsackievirus B3 (CVB3)-induced diseases such as myocarditis and cardiomyopathy. Recent
work in CAR-deficient animals has indicated a role in embryonic development and remodeling with cardiac mal-
formation and lethality.
Methods We generated a tamoxifen-inducible knockout (KO) mouse to study CAR in the adult heart after CVB3 infection.
Histomorphology, virus distribution, and cardiac function were compared in CAR-KO versus noninduced litter-
mate control animals expressing wild-type CAR (WT).
Results We have demonstrated that eliminating CAR prevents signs of inflammatory cardiomyopathy, with essentially
no pathology in KO hearts. Unlike CVB3-infected WT control animals, the cardiac inducible KO mice did not ex-
hibit structural changes such as monocyte infiltration or fibrosis after CVB3 infection or increased production
of markers of inflammation such as interleukin-6 and -10. Whereas CVB3 infection resulted in severe contractile dys-
function in the hearts of animals that express WT, the CAR-deficient hearts appeared normal.
Conclusions Elimination of CAR in adult hearts can efficiently block virus entry and the associated pathology including con-
tractile dysfunction. The lack of infiltration or other morphological changes in CVB3-infected KO hearts empha-
sizes the contribution of direct virus-mediated pathology in enteroviral myocarditis. (J Am Coll Cardiol 2009;
53:1219–26) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.10.064a
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toxsackievirus B3 (CVB3) infections are frequent causes of
uman acute myocarditis, often resulting in chronic cardio-
yopathy with fibrosis and reduced contractile function
hat might progress into terminal heart failure. The cellular
eceptors of CVB3 are the Coxsackievirus-adenovirus re-
eptor (CAR) and the decay-accelerating factor (DAF)/
D55 (1–4). CAR is a 46 kD type I transmembrane
rotein of the tight junction and intercalated discs, where it
ediates homotypic cell adhesion through its extracellular
g-domains (5). The cytoplasmic tail is alternatively spliced
rom *Neuromuscular and Cardiovascular Cell Biology, Max-Delbrück-Center for
olecular Medicine, Berlin, Germany; †Department of Cardiology, Charité–
ampus Benjamin Franklin, Berlin, Germany; ‡Department of Molecular Pathology,
niversity Hospital Tübingen, Tübingen, Germany; and the §Department of
eterinary and Comparative Anatomy, Pharmacology, and Physiology, Washington
tate University, Pullman, Washington. This study was supported by the DFG SFB
R19. Dr. Shi and Miss Chen contributed equally to this work.m
Manuscript received July 30, 2008; revised manuscript received September 16,
008, accepted October 7, 2008.nd interacts with various adaptor proteins that link to
ignal transduction and endocytosis (5–8). CAR is ex-
ressed in a variety of tissues, including the heart, brain, and
ancreas (1,2,9). It is highly regulated in the developing
eart and significantly reduced after birth, which suggests a
ole in remodeling of the embryonic heart (9). Various
AR-deficient animal models have been generated to gain
See page 1227
dditional insight into its physiological functions (10–12).
argeting either exon 1 or 2 results in cardiac malformation,
egeneration, and lethality in mid-gestation of the conven-
ional knockouts (KOs). These phenotypes indicate a role
or CAR in morphogenesis and differentiation of the heart.
n addition to providing a genetic tool to generate loss of
unction mutants, the mouse is also a suitable animal model
o study the role of CAR in CVB3-induced pancreatitis and
yocarditis, because pathomechanisms and disease progres-
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Coxsackievirus-Adenovirus Receptor Knockout Prevents Myocarditis April 7, 2009:1219–26sion are similar in human pa-
tients and mice (13,14). The
objective of this study is to inves-
tigate the role of CAR in viral
myocarditis. Elimination of
CAR in the adult heart can abol-
ish cardiac CVB3 infection and
prevent the evolvement of myo-
carditis and consequently of fi-
brosis and reduced contractile
function.
Methods
Generation of inducible CAR-
KO mice. To generate CAR-
deficient animals we assembled
a targeting construct flanking
CAR exon 1, which contains the
ATG, with lox sites (Fig. 1A).
This strategy precludes expres-
sion of both the membrane-
bound and soluble CAR isoforms.
After homologous recombination,
blastocyst injection of embryonic
stem cells was used to obtain KO
animals. The neomycine/flp resis-
tance cassette was removed by
germline expression of the FLP
recombinase (15). The resulting
nimals were verified by polymerase chain reaction and
outhern blot (Figs. 1B and 1C) and maintained on a mixed
29SVJ/C57black6 background breeding MerCreMer
ransgenic (MCM) (16) CAR(RECf/RECf) floxed animals to
CM CAR(RECf/RECf) animals. This approach yields
0% littermate control subjects that express wild-type CAR
WT). Tamoxifen in peanut-oil (10 g/l) was injected
nto animals at 2 months of age. Five injections/week for 2
onsecutive weeks (10 injections; 300 mg/kg total) resulted
n a 10-fold difference in CAR expression levels after 3
onths (Fig. 1D). All experiments involving animals were
arried out following institutional and National Institutes of
ealth guidelines, “Using Animals in Intramural Research.”
irus and mice. Complementary deoxyribonucleic acid-
enerated CVB3 Nancy strain (17) was grown and propa-
ated in Vero cells. Stock virus was prepared by 3 freezing
nd thawing and purified by sucrose gradient centrifugation.
he same stock was used to infect mice by intraperitoneal
IP) injection with 5  104 plaque-forming units purified
VB3 3 months after induction with tamoxifen. We did
ot detect any background specific differences in virus
nfection, comparing the mixed 129SVJ/C57black6 and
ither parental strain (data not shown). Animals were
illed at 10 or 28 days after injection with virus (p.i.);
oninfected KO and Cre-negative animals were used as
Abbreviations
and Acronyms
CAR  Coxsackievirus-
adenovirus receptor
CVB3  Coxsackievirus B3
DAF  decay-accelerating
factor
FAM  carboxyfluorescein
IL  interleukin
INF  interferon
KO  knockout
LCK  lymphocyte protein
tyrosine kinase
LV  left
ventricle/ventricular
MCM  MerCreMer
transgenic
p.i.  after injection
with virus
TAMRA  carboxy-
tetramethy-lrhodamine
TNF  tumor necrosis
factor
WT  noninduced
littermate control animals
expressing wild-type
Coxsackievirus-adenovirus
receptorontrol subjects. Cissue preparation. Samples of aseptically removed tissues
ere either fixed for 12 h in phosphate-buffered (pH 7.2)
% paraformaldehyde and embedded in paraffin for histol-
gy, in situ hybridization, or quick-frozen in liquid nitrogen
or subsequent preparation of ribonucleic acid (RNA) and
rotein.
istopathology. Histological analysis was performed on
eparaffinized 5-m-thick tissue sections that were stained
ith hematoxylin and eosin to assess cellular injury and
nflammation (18). Masson’s Trichrome stain was used to
isualize the degree of fibrosis. Immunohistochemistry was
sed to follow CVB3 infection with the VP1 antibody as
ublished previously (19).
n situ hybridization and quantification of CVB3 infec-
ion. Localization of CVB3 RNA in paraffinated tissue
ections was done by radioactive in situ hybridization. At
he indicated time points, tissue samples were fixed in 4%
araformaldehyde/0.1 mol/l sodium phosphate buffer (pH
.2) and embedded in paraffin for detection of viral RNA
ith a 35S-labeled enterovirus-specific RNA probe as pre-
iously described (18). Tissue sections were exposed for 3
eeks and counterstained with hematoxylin and eosin. The
etection of replication is a robust and sensitive method to
ocument virus-infected cells. Lacking sensitive assays for
irus entry in vivo and because CAR has never been implied
n replication of CVB3, we used in situ hybridization to
etect replication as a measure for virus entry dependent on
AR. To quantify the area fraction of infection, we used
mageJ version 14.1k (National Institutes of Health, Be-
hesda, Maryland) as outlined in the user manual.
xpression analysis. The RNA from heart, pancreas, spleen,
ut, liver, lung, and kidney was isolated from individual
ice and amplified with TaqMan probes for CAR, inter-
eukin (IL)-6, IL-10, tumor necrosis factor (TNF), lym-
hocyte protein tyrosine kinase (LCK), interferon (IFN)
VB3, and glyceraldehyde-3-phosphate dehydrogenase
for normalization) as described previously (20). The probe-
ets used are as follows: CAR-AGCTGCACGGTTC-
AAACAGA (forward), TTCCGGCTCGGTTGGA
reverse), 6-FAM-CTCTGACCAGTGTATGCT-
CGACTAGACGT-TAMRA (probe); IL-6-ACA-
GTCGGAGGCTTAATTACACAT (forward),
TGCCATTGCACAACTCTTTTC (reverse), 6-FAM-
TCTCTGGGAAATCGTGGAAATG-TAMRA (probe,
xon 2); IL-10-CCAGAGCCACATGCTCCTAGA
forward), GGTCCTTTGTTTGAAAGAAAGTCTTC
reverse), 6-FAM-CTGCGGACTGCCTTCAGCCAGG-
AMRA (probe); TNF-CATCTTCTCAAAATTCGA-
TGACAA (forward), CCAGCTGCTCCTCCACTTG
reverse), 6-FAM-CCTGTAGCCCACGTCGTAGCAAA-
CA-TAMRA (probe); IFN-CAGCAACAGCAAGG-
GAAA (forward), CTGGACCTGTGGGTTGTTGAC
reverse), 6-FAM-AGGATGCATTCATGAGTATTG-
CAAGTTTGA-TAMRA (probe); CVB3 (M16572)-
CCTGAATGCGGCTAATCC (forward), AAACA-
GGACACCCAAAGTAGTC (reverse), 6-FAM-CG-
1221JACC Vol. 53, No. 14, 2009 Shi et al.
April 7, 2009:1219–26 Coxsackievirus-Adenovirus Receptor Knockout Prevents MyocarditisFigure 1 Tamoxifen Inducible Cardiac Specific CAR Knockout
(A) Targeting strategy: Exon 1, which contains the translation start is replaced with the floxed exon 1 and the flippase recognition target (FRT) flanked neo-cassette. The
neo-cassette is subsequently removed through germline expression of the flippase (FLP) recombinase. (B) Polymerase chain reaction (PCR)-based genotyping with the
primers indicated in (A) was used to detect the fragments corresponding to wild-type (WT), NEO, 3rd-lox, and RECf allele. The colony was established by mating FLP
transgenics [1] to targeted animals [2]. The resulting double heterozygous animals [3] were used to obtain floxed heterozygous [4] and homozygous animals [5]. (C) For
Southern blot genomic DNA was digested with BamHI, hybridized with a 600 bp PCR product (probe). The 12-kb WT allele and the 4.4-kb RECf allele were used to distin-
guish WT [1], knockout (KO) [2], and heterozygous animals [3]. Coxsackievirus-adenovirus receptor (CAR) ribonucleic acid (D) and protein levels (F) are altered with a
strong effect in MerCreMer transgenic animals 3 months after the tamoxifen treatment, whereas the expression of the coreceptor decay-accelerating factor (DAF) was
not significantly changed (E); n  3/group; **p  0.01; ***p  0.001.
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Coxsackievirus-Adenovirus Receptor Knockout Prevents Myocarditis April 7, 2009:1219–26TGCAGAGTTGCCCGTTACGA-TAMRA (probe);
lyceraldehyde-3-phosphate dehydrogenase-GGCAA-
TTCAACGGCACAGT (forward), AGATGGTG-
TGGGCTTCCC (reverse), 6-FAM-AGGCCGAG-
ATGGGAAGCTTGTCATC-TAMRA (probe);
CK–CCTTCAACTTCGTGGCGAAA (forward), CG-
CCTTACGGCTCAGATTCTT (reverse), 6-FAM-
AACAGCCTGGAGCCTGAACCTTGG-TAMRA
probe). The DAF1 gene expression assay was purchased
rom Applied Biosystems (Foster City, California).
Protein was isolated by homogenization in liquid nitrogen
nd lysis in 8 mol/l urea, 4% CHAPS with DDT (80 mmol/l
nal) and protease inhibitor (PMSF). After electrophoresis on
2% sodium dodecyl sulfate polyacrylamide gel electrophoresis,
amples were transferred to nitrocellulose-membrane
ybond-C extra (GE Healthcare, Piscataway, New Jersey).
embranes were blocked with 5% skim milk in phosphate-
uffered saline–Tween 20 followed by incubation with com-
ercial antibodies against CAR (rabbit polyclonal, Santa Cruz
iotechnology, Santa Cruz, California) and -actin (mouse
onoclonal, Sigma, St. Louis, Missouri) according to the
anufacturer’s instructions and detected with horseradish
Figure 2 Removal of CAR in Adult Cardiomyocytes Prevents Vi
(A) After infection with Coxsackievirus B3, WT animals show myocyte necrosis and infl
mals. (B) Trichrome staining reveals increased collagen deposition in areas of the car
after injection with virus (p.i.) in the heart of WT mice. Scale bar  50 m. (C, D) Afte
tumor necrosis factor (TNF) were elevated in either genotype, with high levels in the
phocyte protein tyrosine kinase (LCK) and interferon (IFN) were 10 different betweroxidase-conjugated secondary antibodies and chemilumi-
escence staining with ECL (SuperSignal West Pico Chemi-
uminescent Substrate, Pierce, Rockford, Illinois).
urgical procedures and hemodynamic measurements. The
nimals were anesthetized (thiopental 125 mg/kg IP),
ntubated, and artificially ventilated. As recently described, a
.4-F microconductance pressure catheter (ARIA SPR-
19, Millar-Instruments, Inc., Houston, Texas) was posi-
ioned in the left ventricle (LV) for continuous registration
f LV pressure–volume loops in an open-chest as described
reviously in a closed-chest model (21). Calibration of the
olume signal was obtained by hypertonic saline (10%)
ash-in technique (22). Systolic function was quantified by
V end-systolic pressure (mm Hg) and dP/dtmax (mm
g/s) as an index of LV contractility. Diastolic function was
easured by LV end-diastolic pressure (mm Hg) and
P/dtmin (mm Hg/s). Global cardiac function was quanti-
ed by the end systolic and diastolic volume (l), ejection
raction (% calculated), and heart rate (beats/min).
tatistical analysis. For statistical analysis, GraphPad Prism
oftware (San Diego, California) was used. Results are ex-
ressed as mean  SEM. For hemodynamic data statistical
ptake and Myocarditis
tion with infiltration of mononuclear cells, which is not detectable in the CAR KO ani-
sion in WT animals but not in CAR KO mice. The fibrotic lesions solidify at day 28
ays or 28 days p.i., markers for inflammation such as interleukin (IL)-6, IL-10, and
mals. (E, F) Cardiac messenger ribonucleic acid levels of inflammation markers lym-
K and IFN; n  36. **p  0.01; ***p  0.001. Abbreviations as in Figure 1.rus U
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April 7, 2009:1219–26 Coxsackievirus-Adenovirus Receptor Knockout Prevents Myocarditisignificance between groups was determined with the Mann-
hitney U test; for expression analysis we used an unpaired
-tailed t test. The significance level was chosen as p  0.05.
esults
ardiac CVB3 infection can be abolished by eliminating
AR. We used a conditional KO mouse (Fig. 1) to evaluate
he role of CAR in CVB3-induced myocarditis in the adult
eart. After 2 weeks of induction with tamoxifen, protein levels
n the KO are 10% of WT levels (Fig. 1D). CVB3 readily
nfects cardiomyocytes in vitro and in vivo (17,18). In our
xperiments we used the CVB3 Nancy strain, which has been
hown to depend on CAR for infection (4). In CVB3-infected
T mice we were able to detect myocyte necrosis and signs of
nflammation as shown by infiltration of mononuclear inflam-
atory cells at day 10 after infection and subsequent fibrosis at
ay 28 (Figs. 2A and 2B). In contrast, the CAR-deficient KO
Figure 3 Virus Entry into the Heart Is Blocked After Deletion o
(A) The distribution of replicating virus was visualized by in situ hybridization with
cardiomyocytes are infected at day 10 after injection with virus (p.i.) as indicated b
(a), whereas not a single virus positive cell could be detected in KO hearts (b). Th
vs. (d, f). Gut, liver, lung, and kidney were not infected in either KO or WT animals
VP1 with focal expression in myocytes at 10 days after infection only in the WT he
Man analysis. Size bar  50 m. (D) Quantification of CVB3 infection in pancreas
was 52.6% in WT and 58.7% in KO (p  0.36) and in spleen was 2% independentearts did not show any significant morphological changes.
he protection of CAR-deficient hearts from myocarditis was
lso reflected by the cardiac messenger RNA levels of the
ytokines IL-6, IL-10, TNF, IFN, and the T-cell protein
CK with only minor elevations in the KO as compared with
he marked increased in WT mice (Figs. 2C to 2F). To
ocument that CAR efficiently blocks virus uptake into cardi-
myocytes, we used in situ hybridization capable of detecting
irus RNA and immunohistochemistry to visualize CVB3-
P1 protein in single infected cardiac cells. As shown in Figure
, virus replication was detected in the heart, pancreas, and
pleen, whereas small intestine, liver, lung, and kidney did not
how signs of infection 10 days after IP infection with CVB3.
e did not detect a single infected cardiomyocyte within 60
issue sections derived from 20 KO hearts, which was unex-
ected. In contrast, virus entry and replication did not differ
etween genotypes in spleen or pancreas at day 10 p.i. (Fig.
e specific to Coxsackievirus B3 (CVB3). In the WT heart, approximately 30% of
silver grain precipitates (dark signal) reflecting the virus ribonucleic acid (RNA)
nt of infection of other susceptible organs was similar in WT and KO mice (c, e)
n). (B) Coxsackievirus protein was detected with an antibody directed against
) Virus RNA was only present in the WT heart at day 10 as determined by Taq-
pleen (n  3/group). At day 10 p.i., the area fraction of infection in pancreas
genotype (p  0.87). Abbreviations as in Figure 1.f CAR
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Coxsackievirus-Adenovirus Receptor Knockout Prevents Myocarditis April 7, 2009:1219–26D) and was identical to our previous observation (23). Hence,
n our inducible CAR-deficient mice only the heart was
rotected from virus entry and subsequent replication.
actors other than CAR expression levels influence
VB3 distribution in target organs. To relate the distri-
ution of virus infection RNA to CAR expression, we
etermined CAR messenger RNA and protein levels for all
issues tested (Figs. 4A and 4B). Not only did CAR
xpression levels differ by up to 25-fold between organs
usceptible for virus infection (spleen vs. pancreas) but,
onversely, tissues that were not susceptible such as gut,
iver, and lung expressed CAR at levels that were 3- to
0-fold higher than cardiac expression.
ardiac function after CVB3 infection. The functional
onsequences of CAR deficiency were evaluated by conduc-
ance catheter. Our results show that contractile function is
aintained after CVB3 infection of CAR KO animals (Fig. 5).
hereas contractile function was impaired in control ani-
als 10 days after infection (reduced contractility and
jection fraction and a trend to reduced developed pressure,
ardiac output, and relaxation), CAR KO animals were
naffected. The maintenance of systolic (ejection fraction,
max, dP/dtmax) and diastolic properties (dP/dtmin as a
easure for active relaxation) in CVB3-infected KO hearts
emonstrates that the elimination of CAR not only prevents
tructural changes but also preserves cardiac function after
Figure 4
Expression of CAR in the Adult Mouse
Heart, Pancreas, Spleen, Gut, Liver, Lung,
and Kidney (Wild-Type Males at 6 Months of Age)
The Coxsackievirus-adenovirus receptor (CAR) messenger RNA (A) and protein
levels (B) differ between tissues but do not correlate with infectivity of the tis-
sue. Low levels of CAR expression are documented for adult heart, spleen, and
kidney. The CAR messenger RNA levels differ 10 in pancreas (Pancr) and
lung. The RNA levels are normalized to heart, n  3. Increased protein expres-
sion was confirmed for pancreas, gut, liver, and lung.nfection with CVB3. riscussion
iral myocarditis is one of the main causes of acute and
hronic heart failure, and coxsackievirus is one of the
mportant causative agents, which—especially in children—
ccounts for a significant fraction of cases of terminal heart
ailure (24). The disease process is mimicked in CVB3-
nfected mice with acute myocarditis that proceeds to a
hronic phase that can ultimately lead to chronic cardiomy-
pathy (25). Here, we study the acute response to CVB3 in
eart-specific CAR KO. To establish the animal model we
nfected a heart-specific tamoxifen-inducible KO with the
ardiotropic CVB3 Nancy strain that has been described to
roduce severe myocarditis in mice (23).
CAR has not only been implicated in the progression of
iral myocarditis on the basis of its function as a virus
eceptor, but various approaches to study CAR in vivo have
ndicated that reduced CAR expression or interference with
AR function could affect the disease process: CAR has
een implicated in the early phases of myocarditis with
educed expression of CAR in MyD-88–deficient mice that
re partially protected from CVB3-induced pathology (26).
lthough less of the virus was present in the MyD-88 KO
ardiomyocytes, it is unclear whether this effect can be attrib-
ted to the reduced expression of CAR or to the concomitantly
ncreased IFN-. Soluble recombinant CAR has been used as
n efficient tool to abolish CVB3-mediated myocarditis in
ice, indicating the importance of the CAR–CVB3 interac-
ion in the disease process (27). Whereas this approach is closer
o the application as a therapeutic strategy, its effects can result
rom interaction of soluble CAR with the virus particle,
ndogenous CAR, or additional extracellular proteins. Here we
ecided to take a loss of function approach to exclusively
nvestigate CAR in the acute phase of CVB3-induced myo-
arditis. With CAR expression reduced to 10% of WT levels,
e were able to completely abolish cardiac pathology in the
VB3-infected KO mice (Fig. 2). Structural changes were
bsent as determined by histology, and not a single infected
ardiomyocyte could be detected by in situ hybridization
ithin a total of 20 investigated KO hearts (Fig. 3). As the
CM transgene directs expression of the recombinase exclu-
ively to the heart, virus replication is retained in both pancreas
nd spleen of KO mice. This might help explain the increase
n TNF expression that—albeit reduced in the CVB3-
nfected CAR KO as compared to the CVB3-infected control
eart—was 3-fold increased as compared with noninfected
nimals on the basis of cardiac RNA levels. Although CAR
xpression has been detected in multiple tissues including
eart, brain, pancreas, liver, lung, and gut (9,28,29), the
ajority of those organs from WT mice did not show signs of
irus infection (gut, liver, lung, and kidney). As confirmed on
he RNA and protein level, these organs do express CAR, at
evels that exceed cardiac expression in gut, liver, and lung that
ere nevertheless not infected. Failure of virus to enter these
ells could derive from the spatial separation of virus and its
eceptor or the insufficient expression of coreceptors or intra-
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April 7, 2009:1219–26 Coxsackievirus-Adenovirus Receptor Knockout Prevents Myocarditisellular adaptor proteins, such as ZO1 and MUPP1 (4,5,7,30).
onversely, low levels of CAR expression as detected in the
pleen do not preclude CVB3 infection. Unlike in the heart,
here most cells are CAR-deficient, permissive cells in the
pleen apparently do express CAR at sufficient levels to become
nfected. Overall, the tissue distribution and expression analysis
ndicate that CAR is necessary but not sufficient for virus entry
n the mouse model of CVB3 infection. Its coreceptor DAF
an by itself not mediate virus uptake as shown by Milstone et
l. (31). There are DAF binding and nonbinding strains of
VB3, but even the DAF binding variant cannot mediate lytic
nfection without CAR (4). Thus, CAR exerts a dominant
ffect on virus entry that in the KO could not be overcome by
AF. In the CAR KO heart DAF expression was not
ignificantly changed (Fig. 1E), indicating that it does not
ontribute to the phenotype.
To verify that CAR deficiency not only prevented mor-
hological changes associated with myocarditis but also
etained normal cardiac function, we analyzed the contrac-
ile and elastic properties of CVB3-infected and untreated
O and WT animals in vivo with the conductance catheter.
n the acute phase CAR-deficient hearts were unaffected,
hereas the CVB3-infected control hearts showed an im-
aired contractile function with a significant reduction in
Figure 5 Effect of CAR Deletion and CVB3 Infection on Cardiac
Contractile function of Coxsackievirus B3 (CVB3)-infected WT hearts is reduced as
infected CAR KO animals. Statistical significance was obtained for contractility (dP
infected versus control KO animals (dark bars in A to E). Animals were investigate
put; SV  stroke volume; Ved  end-diastolic volume; Ves  end-systolic volume;arameters of systolic function. cIn addition to documenting the crucial role of CAR in
irus entry into the heart in vivo, the established animal
odel provides novel insights into the pathogenesis of
VB-induced myocarditis. It has been argued that CVB
yocarditis (at least, the chronic phase of disease) is
utoimmune in nature. Because the MCM transgene is not
xpressed in T-cells, there is no reason to expect that
utative autoreactive T-cells would not be induced in the
onditional CAR KO. Here we show that virus infection of
ardiomyocytes is a prerequisite for myocarditis and that—
ven as late as 28 days after infection—the KO-heart looks
ormal. All other susceptible organs can become infected
nd show the expected pathology in the CAR KO. This
uggests a critical role for the productive infection of
ardiomyocytes in the disease and argues against a primary
utoimmune component in the pathogenesis.
So far, various therapeutic approaches to combat CVB3
nfection have been proposed using CAR-transgenic erythro-
ytes to redirect and capture virus particles (32) or soluble
AR to compete with the cell surface receptor (27,33,34).
hereas the former has led to reduced lethality, the latter
as worked in tissue culture (35) but produced inconsistent
esults in vivo, either ameliorating or aggravating the disease
rocess in mice (27,33,34). On the basis of our findings, one
ction
ared with noninfected WT control animals unlike that of infected versus non-
) (B) and ejection fraction (D). In contrast, cardiac function is preserved in
days after CVB3 infection; n  30. *p  0.05; **p  0.01. CO  cardiac out-
abbreviations as in Figure 1.Fun
comp
/dtmax
d 10
otherould speculate that CAR indeed provides a suitable target
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Coxsackievirus-Adenovirus Receptor Knockout Prevents Myocarditis April 7, 2009:1219–26n the prevention and possible treatment of viral myocardi-
is, although future analysis will have to address potential
nwanted effects that might be associated with the loss of
AR in the adult heart (36).
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